gene therapy – Talk Bio

Lilly Expands Gene Therapy Presence with Acquisition of Adverum Biotechnologies

2 days ago talkbio0Tagged Acquisition, Adverum Biotechnologies, contingent value, eli lilly, gene therapy, ixovec, Ophthalmology specialty, Wet Age-Related Macular Degeneration

Eli Lilly; Adverum Biotechnologies; gene therapy; ophthalmology; wet age-related macular degeneration; ixovec; acquisition; contingent value rights

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

4 days ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

7 days ago talkbio0Tagged Biotechnology, board of directors, Clinical Development, Dimitri Azar, Diorasis, gene therapy, Glaucoma, Ophthalmology specialty, United States Food and Drug Administration

Diorasis Therapeutics; Dimitri Azar; Board of Directors; gene therapy; glaucoma; ophthalmology; biotechnology; FDA; clinical development

Recent Advances and News in In Vivo Therapeutic Technologies (2025)

1 week ago talkbio0Tagged Acquisitions, Autoimmune Diseases, CAR-T, Cell Therapy, drug delivery innovation, Fast Track, gene therapy, in vivo, nanoparticle delivery, Neoplasms, RNA delivery, United States Food and Drug Administration

in vivo CAR-T; cell therapy; gene therapy; RNA delivery; autoimmune disease; oncology; nanoparticle delivery; drug delivery innovation; FDA fast track; biotech acquisitions

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for Neurotrophic Keratitis

2 weeks ago talkbio0Tagged gene therapy, HSV-1 viral vector, KB801, Krystal Biotech, Neurotrophic keratitis, platform technology designation, redesable eye drop, United States Food and Drug Administration, VYJUVEK

Krystal Biotech; FDA; platform technology designation; HSV-1 viral vector; KB801; gene therapy; neurotrophic keratitis; redesable eye drop; VYJUVEK

Gene Therapy Delivers Long-Term Immune Protection in Children With Rare Immune Disorders

2 weeks ago talkbio0Tagged Adenosine deaminase deficiency, Clinical Trials, Combined immunodeficiency disease, Congenital leukocyte adherence deficiency, Curative Therapy, gene therapy, immune protection, Leukocyte adhesion deficiency type 1, Long-term, Pediatric immunology, Rare Diseases, Severe (severity modifier)

gene therapy; long-term immune protection; ADA-SCID; severe combined immunodeficiency; LAD-I; leukocyte adhesion deficiency; rare disease; pediatric immunology; clinical trial; curative treatment

Regeneron Heads to FDA Seeking Approval for Game-Changing Hearing Loss Gene Therapy

2 weeks ago talkbio0Tagged Approved, CHORD trial, DB-OTO, Deafness, gene therapy, OTOF gene, Regeneron, United States Food and Drug Administration

Regeneron; hearing loss; gene therapy; DB-OTO; FDA approval; OTOF gene; CHORD trial

Patient with Preexisting Immunity to AAV Vectors Granted Gene Therapy After Antibody-Depleting Agent Allowed Eligibility

2 weeks ago talkbio0Tagged AAV antibodies, antibody-chopping drug, Clinical Trials, Eligibility Determination, gene therapy

gene therapy; AAV antibodies; ineligible; antibody-chopping drug; clinical trial; eligibility

AviadoBio Secures Option to Develop Rare Eye Disease Gene Therapy UGX-202 in $413 Million Deal with China’s UgeneX

2 weeks ago talkbio0Tagged AviadoBio, China, gene therapy, Optogenetics, Retinitis Pigmentosa, UgeneX, UGX-202

AviadoBio; UgeneX; UGX-202; optogenetics; gene therapy; retinitis pigmentosa; China; $413 million deal

AviadoBio Secures Option to UgeneX’s UGX-202 Gene Therapy for Retinal Disease

2 weeks ago talkbio0Tagged AviadoBio, Clinical Development, Dependovirus, gene therapy, Optogenetics, Retinal Diseases, Retinitis Pigmentosa, UGX-202

AviadoBio; UgeneX Therapeutics; UGX-202; retinitis pigmentosa; gene therapy; optogenetics; adeno-associated virus (AAV); exclusive option; retinal disease; clinical development